                         LISTAGEM DE SEQUNCIAS

<110>  Fundaao Oswaldo Cruz
 
<120>  PROTEINA, POLINUCLEOTDEO, VETOR, CLULA HOSPEDEIRA, COMPOSIO, 
       MTODO PARA TRATAR UMA DOENA, MTODO IN VITRO PARA PROGNOSTICAR 
       ESCLEROSE MLTIPLA, E, USO DE UMA PROTENA OU COMPOSIO

<130>  P141909 (caso 196)

<160>  15    

<170>  PatentIn version 3.5

<210>  1
<211>  711
<212>  DNA
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  1
gacgtggtga tgacccagag ccccctgagc ctgcccgtga cccccggcga gcccgccagc       60

atcagctgca ggagcagcca gagcctggcc aagagctaca gcaacaccta cctgagctgg      120

tacctgcaga agcccggcca gagcccccag ctgctgatct acggcatcgg caacggcggc      180

agcggcgtgc ccgccaggtt cagcggcagc ggcagcggca ccgacttcac cctgctgatc      240

agcagggtgg aggccgagga cgtgggcgtg tactactgcc tgcagggcac ccaccagccc      300

tacaccttcg gccagggcac caaggtggag atcggcggcg gcggcagcca ggtgcagctg      360

gtgcagagcg gcgccgaggt gaagaagccc ggcgccagcg tgaaggtgag ctgcaagggc      420

agcggctaca ccttcaccag ctactggatg cactgggtga ggcaggcccc cggccagagg      480

ctggagtgga tcggcgagat cggccccagc gagagcaaca ccaactacaa ccagaagttc      540

aagggcaggg tgaccctgac cgtggacatc agcgccagca ccgcctacat ggagctgagc      600

agcctgagga gcgaggacac cgccgtgtac tactgcgcca ggggcggcta cgccggctgg      660

gactacgcca tcgactactg gggccagggc accctggtga ccgtgagcag c               711


<210>  2
<211>  711
<212>  DNA
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  2
gacgttgtaa tgactcaatc gccactttct ttacctgtaa ctcccggtga acctgcgtct       60

atttcgtgtc gcagtagtca gtctctggcc aagtcttatt ccaatactta cctgtcctgg      120

tatcttcaaa agcctggaca gtcaccacaa cttttaatat atggcattgg gaatggcggg      180

agtggagtgc ctgctcgttt cagcggctct ggtagcggaa cagacttcac attactgatt      240

agtcgtgtcg aagctgaaga cgttggagtg tactactgct tgcaagggac ccatcagcct      300

tacacgtttg gccaaggcac taaagtggag ataggcggcg gcggcagtca ggttcagtta      360

gtccaaagtg gggccgaggt taagaagccc ggcgcttctg tcaaagtctc gtgtaagggc      420

agtggctaca cgttcacatc atactggatg cactgggtac ggcaagctcc tggtcagaga      480

ctggagtgga tcggcgagat tggaccctcc gagagcaata cgaactataa ccaaaaattc      540

aaaggacgcg tcacactgac ggtcgacata tctgcttcga cggcatacat ggaattaagt      600

tctcttagaa gtgaagacac ggcagtatat tactgcgctc gtggaggata tgctggttgg      660

gactacgcga ttgactactg gggccaaggt actcttgtca cggtcagtag c               711


<210>  3
<211>  237
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  3

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Ala Lys Ser 
            20                  25                  30          


Tyr Ser Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Gly Ile Gly Asn Gly Gly Ser Gly Val Pro 
    50                  55                  60                  


Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Leu Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Gly 
                85                  90                  95      


Thr His Gln Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Gly 
            100                 105                 110         


Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 
        115                 120                 125             


Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr 
    130                 135                 140                 


Phe Thr Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Arg 
145                 150                 155                 160 


Leu Glu Trp Ile Gly Glu Ile Gly Pro Ser Glu Ser Asn Thr Asn Tyr 
                165                 170                 175     


Asn Gln Lys Phe Lys Gly Arg Val Thr Leu Thr Val Asp Ile Ser Ala 
            180                 185                 190         


Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 
        195                 200                 205             


Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Ala Gly Trp Asp Tyr Ala Ile 
    210                 215                 220                 


Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
225                 230                 235         


<210>  4
<211>  243
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  4

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Ala Lys Ser 
            20                  25                  30          


Tyr Ser Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Gly Ile Gly Asn Gly Gly Ser Gly Val Pro 
    50                  55                  60                  


Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Leu Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Gly 
                85                  90                  95      


Thr His Gln Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Gly 
            100                 105                 110         


Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 
        115                 120                 125             


Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr 
    130                 135                 140                 


Phe Thr Ser Tyr Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Arg 
145                 150                 155                 160 


Leu Glu Trp Ile Gly Glu Ile Gly Pro Ser Glu Ser Asn Thr Asn Tyr 
                165                 170                 175     


Asn Gln Lys Phe Lys Gly Arg Val Thr Leu Thr Val Asp Ile Ser Ala 
            180                 185                 190         


Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 
        195                 200                 205             


Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Ala Gly Trp Asp Tyr Ala Ile 
    210                 215                 220                 


Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser His His His 
225                 230                 235                 240 


His His His 
            


<210>  5
<211>  111
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  5

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Ala Lys Ser 
            20                  25                  30          


Tyr Ser Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Gly Ile Gly Asn Gly Gly Ser Gly Val Pro 
    50                  55                  60                  


Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Leu Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Gly 
                85                  90                  95      


Thr His Gln Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
            100                 105                 110     


<210>  6
<211>  121
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  6

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Gly Pro Ser Glu Ser Asn Thr Asn Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Leu Thr Val Asp Ile Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Tyr Ala Gly Trp Asp Tyr Ala Ile Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  7
<211>  19
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  7

Ser Cys Arg Ser Ser Gln Ser Leu Ala Lys Ser Tyr Ser Asn Thr Tyr 
1               5                   10                  15      


Leu Ser Trp 
            


<210>  8
<211>  13
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  8

Leu Ile Tyr Gly Ile Gly Asn Gly Gly Ser Gly Val Pro 
1               5                   10              


<210>  9
<211>  10
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  9

Leu Gln Gly Thr His Gln Pro Tyr Thr Phe 
1               5                   10  


<210>  10
<211>  11
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  10

Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His 
1               5                   10      


<210>  11
<211>  19
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  11

Glu Ile Gly Pro Ser Glu Ser Asn Thr Asn Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly Arg Val 
            


<210>  12
<211>  14
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  12

Gly Gly Tyr Ala Gly Trp Asp Tyr Ala Ile Asp Tyr Trp Gly 
1               5                   10                  


<210>  13
<211>  5
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  13

Gly Gly Gly Gly Ser 
1               5   


<210>  14
<211>  10
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  14

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10  


<210>  15
<211>  15
<212>  PRT
<213>  Sequncia Artificial

<220>
<223>  scFv anti-VLA-4

<400>  15

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


